R-DXd: Clinical Trials

5 recruiting, 3 active not recruiting, 1 not yet recruiting. 5 Phase 2, 4 Phase 3, 2 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	5	Recruiting 3, Active not recruiting 2
Phase 3	4	Recruiting 3, Not yet recruiting 1
Phase 1	2	Active not recruiting 2

Follow R-DXd: new trials by email Literature Review of R-DXd trials Research Report on R-DXd

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	646	2026-10-07	2026-10-30
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer	Phase 3	Not yet recruiting	Daiichi Sankyo	600	2026-10-01	2026-09-01
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) R-DXd, Bevacizumab - Ovarian Cancer, Ovarian Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	802	2026-09-18	2026-10-29
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) R-DXD, I-DXD, Docetaxel - Lung Neoplasm	Phase 2	Recruiting	Merck Sharp & Dohme LLC	144	2025-05-28	2026-10-07
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) Raludotatug Deruxtecan, Ifinatamab Deruxtecan, Docetetaxel - Carcinoma, Non-Small-Cell Lung	Phase 2	Recruiting	Merck Sharp & Dohme LLC	96	2025-05-13	2026-10-27
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) Raludotatug deruxtecan - Advanced Solid Tumor, Metastatic Solid Tumors	Phase 2	Active not recruiting	Daiichi Sankyo	335	2025-01-06	2026-09-24
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer R-DXd, Paclitaxel, Topotecan - Solid Cancer	Phase 2 / Phase 3	Recruiting	Daiichi Sankyo	860	2024-02-27	2026-10-26
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830 - Small Cell Lung Carcinoma	Phase 1 / Phase 2	Active not recruiting	Merck Sharp & Dohme LLC	110	2021-08-19	2026-06-01
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors DS-6000a - Renal Cell Carcinoma, Ovarian Tumor	Phase 1	Active not recruiting	Daiichi Sankyo	179	2020-12-22	2026-09-04

Conditions studied

Ovarian Neoplasms (5)  ·  Fallopian Tube Neoplasms (4)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Lung Neoplasms (1)  ·  Small Cell Lung Carcinoma (1)

Sponsors

Merck Sharp & Dohme LLC (5)  ·  Daiichi Sankyo (4)

Countries

United States (8)  ·  Israel (5)  ·  Italy (5)  ·  Spain (5)  ·  Poland (4)  ·  South Korea (4)  ·  China (3)  ·  Germany (3)  ·  Greece (3)  ·  Hungary (3)  ·  Japan (3)  ·  Taiwan (3)  ·  Turkey (Türkiye) (3)  ·  Australia (2)  ·  Canada (2)

NIH funding

2025 (3), 2023 (1)